Literature DB >> 20442440

Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1.

Barbara J Bain.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20442440      PMCID： PMC2864371          DOI： 10.3324/haematol.2009.021675

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  20 in total

1.  The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors.

Authors:  Els Lierman; Idoya Lahortiga; Helen Van Miegroet; Nicole Mentens; Peter Marynen; Jan Cools
Journal:  Haematologica       Date:  2007-01       Impact factor: 9.941

2.  Molecular characterization of the t(8;13)(p11;q12) translocation associated with an atypical myeloproliferative disorder: evidence for three discrete loci involved in myeloid leukemias on 8p11.

Authors:  I H Still; O Chernova; D Hurd; R M Stone; J K Cowell
Journal:  Blood       Date:  1997-10-15       Impact factor: 22.113

3.  Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.

Authors:  Christian Elling; Philipp Erben; Christoph Walz; Marie Frickenhaus; Mirle Schemionek; Martin Stehling; Hubert Serve; Nicholas C P Cross; Andreas Hochhaus; Wolf-Karsten Hofmann; Wolfgang E Berdel; Carsten Müller-Tidow; Andreas Reiter; Steffen Koschmieder
Journal:  Blood       Date:  2011-01-11       Impact factor: 22.113

Review 4.  A fourth case of 8p11 myeloproliferative disorder transforming to B-lineage acute lymphoblastic leukaemia. A case report.

Authors:  M JabbarAl-Obaidi; N Rymes; P White; M Pomfret; H Smith; J Starczynski; R Johnson
Journal:  Acta Haematol       Date:  2002       Impact factor: 2.195

5.  Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma.

Authors:  G Metzgeroth; C Walz; J Score; R Siebert; S Schnittger; C Haferlach; H Popp; T Haferlach; P Erben; J Mix; M C Müller; H Beneke; L Müller; F Del Valle; W E Aulitzky; G Wittkowsky; N Schmitz; C Schulte; K Müller-Hermelink; E Hodges; S J Whittaker; F Diecker; H Döhner; P Schuld; R Hehlmann; A Hochhaus; N C P Cross; A Reiter
Journal:  Leukemia       Date:  2007-03-22       Impact factor: 11.528

6.  About the t(8;13)(p11;q12) clinico-pathologic entity.

Authors:  L Michaux; C Mecucci; E R Pereira Velloso; J Dierlamm; A Criel; A Louwagie; A van Orshoven; H van den Berghe
Journal:  Blood       Date:  1996-02-15       Impact factor: 22.113

7.  Molecular analysis of chronic eosinophilic leukemia with t(4;10) showing good response to imatinib mesylate.

Authors:  Haruko Tashiro; Ryosuke Shirasaki; Mitsuho Noguchi; Moritaka Gotoh; Kazuo Kawasugi; Naoki Shirafuji
Journal:  Int J Hematol       Date:  2006-06       Impact factor: 2.490

8.  Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.

Authors:  Marianna David; Nicholas C P Cross; Sonja Burgstaller; Andrew Chase; Claire Curtis; Raymond Dang; Martine Gardembas; John M Goldman; Francis Grand; George Hughes; Francoise Huguet; Louise Lavender; Grant A McArthur; Francois X Mahon; Giorgio Massimini; Junia Melo; Philippe Rousselot; Robin J Russell-Jones; John F Seymour; Graeme Smith; Alastair Stark; Katherine Waghorn; Zariana Nikolova; Jane F Apperley
Journal:  Blood       Date:  2006-09-07       Impact factor: 22.113

9.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

Authors:  Jan Cools; Daniel J DeAngelo; Jason Gotlib; Elizabeth H Stover; Robert D Legare; Jorges Cortes; Jeffrey Kutok; Jennifer Clark; Ilene Galinsky; James D Griffin; Nicholas C P Cross; Ayalew Tefferi; James Malone; Rafeul Alam; Stanley L Schrier; Janet Schmid; Michal Rose; Peter Vandenberghe; Gregor Verhoef; Marc Boogaerts; Iwona Wlodarska; Hagop Kantarjian; Peter Marynen; Steven E Coutre; Richard Stone; D Gary Gilliland
Journal:  N Engl J Med       Date:  2003-03-27       Impact factor: 91.245

10.  PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.

Authors:  Jing Chen; Daniel J Deangelo; Jeffery L Kutok; Ifor R Williams; Benjamin H Lee; Martha Wadleigh; Nicole Duclos; Sarah Cohen; Jennifer Adelsperger; Rachel Okabe; Allison Coburn; Ilene Galinsky; Brian Huntly; Pamela S Cohen; Thomas Meyer; Doriano Fabbro; Johannes Roesel; Lolita Banerji; James D Griffin; Sheng Xiao; Jonathan A Fletcher; Richard M Stone; D Gary Gilliland
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-24       Impact factor: 11.205
View more
  16 in total

1.  Mediastinal Mass with Hyper-eosinophilia in a Young Boy -A Diagnostic Dilemma.

Authors:  Abdul Shahid Poovathum Parambil; Shruti Prem; Priya Mary Jacob; Rekha Appukuttan Nair
Journal:  J Clin Diagn Res       Date:  2016-07-01

Review 2.  Therapy-related acute myeloid leukemia with eosinophilia, basophilia, t(4;14)(q12;q24) and PDGFRA rearrangement: a case report and review of the literature.

Authors:  Jun Zhou; Peter Papenhausen; Haipeng Shao
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

3.  Diagnostic application of next-generation sequencing in ZMYM2-FGFR1 8p11 myeloproliferative syndrome: A case report.

Authors:  Yadan Wang; Xiaofei Wu; Jun Deng; Hao Yu; Ren Xu; Zhiyi Zhu; Shichun Tu; Yu Hu
Journal:  Cancer Biol Ther       Date:  2016-08-02       Impact factor: 4.742

4.  Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia.

Authors:  Monica Kasbekar; Valentina Nardi; Paola Dal Cin; Andrew M Brunner; Meghan Burke; Yi-Bin Chen; Christine Connolly; Amir T Fathi; Julia Foster; Molly Macrae; Steven L McAfee; Kristin McGregor; Rupa Narayan; Aura Y Ramos; Tina T Som; Meghan Vartanian; Robb S Friedman; Karim A Benhadji; Gabriela S Hobbs
Journal:  Blood Adv       Date:  2020-07-14

Review 5.  Clinical and Molecular Approach to Adult-Onset, Neoplastic Monocytosis.

Authors:  Rory M Shallis; Alexa J Siddon; Amer M Zeidan
Journal:  Curr Hematol Malig Rep       Date:  2021-04-22       Impact factor: 3.952

6.  Massive thromboembolism owing to the left ventricular thrombus associated with the hypereosinophilic syndrome.

Authors:  Ji Seong Kim; Samina Park; Hyung-Kwan Kim; Yun-Seok Jeon; Seung-Kee Min; Ho Young Hwang
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2014-10-05

Review 7.  New Insights in the Cytogenetic Practice: Karyotypic Chaos, Non-Clonal Chromosomal Alterations and Chromosomal Instability in Human Cancer and Therapy Response.

Authors:  Nelson Rangel; Maribel Forero-Castro; Milena Rondón-Lagos
Journal:  Genes (Basel)       Date:  2017-06-03       Impact factor: 4.096

Review 8.  The serum tryptase test: an emerging robust biomarker in clinical hematology.

Authors:  Peter Valent; Wolfgang R Sperr; Karl Sotlar; Andreas Reiter; Cem Akin; Jason Gotlib; Hans-Peter Horny; Michel Arock
Journal:  Expert Rev Hematol       Date:  2014-08-28       Impact factor: 2.929

9.  Whole-exome sequencing and genome-wide methylation analyses identify novel disease associated mutations and methylation patterns in idiopathic hypereosinophilic syndrome.

Authors:  Christen Lykkegaard Andersen; Helene Myrtue Nielsen; Lasse Sommer Kristensen; Alexandra Søgaard; Jonas Vikeså; Lars Jønson; Finn Cilius Nielsen; Hans Hasselbalch; Ole Weis Bjerrum; Vasu Punj; Kirsten Grønbæk
Journal:  Oncotarget       Date:  2015-12-01

10.  Acute myeloid leukemia with t(4;12)(q12;p13): an aggressive disease with frequent involvement of PDGFRA and ETV6.

Authors:  Jingyi Li; Jie Xu; Lynne V Abruzzo; Guilin Tang; Shaoying Li; M James You; Gary Lu; Elias J Jabbour; Qi Deng; Carlos E Bueso-Ramos; L Jeffrey Medeiros; C Cameron Yin
Journal:  Oncotarget       Date:  2017-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.